The multiplicative expansion of modalities, targets, and diseases creates many new opportunities but challenges the traditional blockbuster model. We examine the evolution of the R&D landscape and its drivers, as the number and diversity of approaches grow and consider implications for development strategy, clinical trials, and ROI.